Compare ZSTK & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZSTK | MBAI |
|---|---|---|
| Founded | 2019 | 2004 |
| Country | Canada | Israel |
| Employees | 21 | 85 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4M | 12.0M |
| IPO Year | N/A | N/A |
| Metric | ZSTK | MBAI |
|---|---|---|
| Price | $4.01 | $1.74 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.4K | ★ 148.9K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.73 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.72 | $1.29 |
| 52 Week High | $11.00 | $3.92 |
| Indicator | ZSTK | MBAI |
|---|---|---|
| Relative Strength Index (RSI) | 39.52 | 53.41 |
| Support Level | $3.72 | $1.35 |
| Resistance Level | $5.86 | $1.91 |
| Average True Range (ATR) | 0.75 | 0.18 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 29.44 | 54.56 |
ZeroStack Corp is an AI focused asset management company. The company also operates a world-wide Commercial and wholesale business through its wholly owned subsidiary. ZeroStack is focused on providing exposure to decentralized AI through a concentrated digital asset approach structured to generate yield and fee-based income from staking validators, compute power technology companies, and complementary businesses within the ecosystem and across the wider AI landscape. The other segment commercial and wholesale (Phatebo and TruHC), which sell pharmaceutical products and mix of products across multiple categories including food and beverage, cannabis accessories and technology, personal care and wellness.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.